Question? Call us
212-363-750060
Days Left
Lead Plaintiff Deadline
Jan 19, 2027
Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material facts concerning the true state of FMC’s distributor-inventory problem, including the extent to which elevated-priced inventory held by distributors was difficult to sell thereby impairing replenishment orders across FMC’s portfolio and threatening the Company’s ability to generate new sales, revenue, EBITDA and cash flow. On October 14, 2026, FMC announced preliminary third quarter 2026 results materially below expectations and sharply reduced its revenue and adjusted EBITDA for the quarter. On this news, the price of FMC’s common stock declined from a closing market price of $8.09 per share on October 14, 2026, FMC’s stock price fell to $5.62 per share on October 15, 2026, a decline of about 31%.
Investors who purchased or otherwise acquired FMC Corporation securities within the class definition described above and suffered losses may be eligible.
If you suffered a loss in FMC Corporation during the relevant time frame or pursuant to the relevant offering(s), you have until January 19, 2027 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
● The Allegation: The complaint alleges that FMC made materially false and misleading statements about its 2026 financial outlook, failing to disclose a worsening distributor-inventory problem in which elevated-priced products held by distributors were difficult to sell, impairing replenishment orders across FMC's portfolio and threatening the company's ability to generate new sales, revenue, EBITDA, and cash flow.
● The Stock Drop: On October 15, 2026, FMC shares fell $2.47 (approximately 31%) to close at $5.62 per share, down from $8.09 per share on October 14, 2026, after the company announced preliminary third quarter 2026 results that fell materially below expectations and sharply reduced its revenue and adjusted EBITDA guidance.
● Class Period & Defendants: The class period runs from February 4, 2026 through October 14, 2026, inclusive. The named defendants are FMC Corporation, Pierre R. Brondeau (Chairman of the Board and Chief Executive Officer), and Andrew D. Sandifer (Executive Vice President and Chief Financial Officer).
● Lead Plaintiff Deadline: January 19, 2027. Investors who wish to seek appointment as lead plaintiff must apply by the deadline.
|
FMC Corporation Class Action Summary |
|
|
Company |
FMC Corporation (NYSE: FMC) |
|
Lead Plaintiff Deadline |
January 19, 2027 |
|
Class Period |
February 4, 2026 – October 14, 2026 |
|
Stock Drop |
October 15, 2026 – FMC fell $2.47 (31%) to $5.62 |
A securities class action lawsuit has been filed against FMC Corporation (NYSE: FMC). The plaintiff brings the case on behalf of investors who bought FMC common stock. The class period runs from February 4, 2026 through October 14, 2026.
The complaint alleges that FMC made materially false and misleading statements about its 2026 financial outlook. The company told investors it was on track to hit its revenue, EBITDA, and cash flow targets. But the lawsuit claims FMC hid a growing distributor-inventory problem. According to the complaint, higher-priced inventory was difficult for distributors to sell, which impaired replenishment orders across FMC’s portfolio.
On October 15, 2026, FMC announced weak preliminary third quarter results. The complaint identifies the announcement as an alleged corrective disclosure. That day, FMC stock fell from $8.09 at the prior close to $5.62 per share, a drop of about 31%. The complaint alleges that investors who bought during the class period suffered losses following the disclosure.
FMC Corporation is an agricultural sciences company that develops, markets, and sells crop protection chemicals across Latin America, North America, Europe, the Middle East, Africa, and Asia. The company markets its products through its own sales organization, alliance partners, independent distributors, and sales representatives. During the class period, FMC common stock traded on the New York Stock Exchange under the symbol FMC.
February 4, 2026–October 14, 2026
Investors who purchased or otherwise acquired FMC Corporation (FMC) common stock during the Class Period may be eligible to seek recovery under the federal securities laws.
The complaint centers on a series of statements FMC and its senior executives made to investors concerning the company's expected 2026 financial performance. Beginning on February 4, 2026, FMC projected full-year revenue of $3.60 billion to $3.80 billion and adjusted EBITDA of $670 million to $730 million. According to the complaint, Chief Executive Officer Pierre R. Brondeau and Chief Financial Officer Andrew D. Sandifer repeatedly expressed confidence in the company's ability to drive growth through new product introductions, higher sales volumes, and manufacturing cost reductions, while navigating competitive pricing pressures affecting its Rynaxypyr and legacy product portfolios.
Throughout the class period, the lawsuit alleges defendants touted anticipated sales growth from the core portfolio, branded Rynaxypyr, and new active ingredients, and reaffirmed the 2026 outlook across multiple earnings calls and investor conferences. On April 29, 2026, FMC reaffirmed its full-year guidance despite a 40 percent decline in first quarter adjusted EBITDA. At investor conferences and on earnings calls, defendants characterized weaker distributor orders and volume fluctuations as temporary shifts related to timing and inventory management.
The complaint alleges these statements were materially false and misleading because FMC was facing a significant distributor-inventory problem that defendants failed to disclose. According to the complaint, elevated-priced inventory held by distributors was difficult to sell, which impaired replenishment orders across FMC's portfolio and threatened the company's ability to generate new sales, revenue, EBITDA, and cash flow. The lawsuit claims this condition made FMC's full-year 2026 financial outlook unlikely to be met, yet defendants provided the public with confident cost-savings and growth projections that did not account for these conditions.
The complaint further alleges defendants knew or recklessly disregarded that these statements were false when made. The complaint alleges that Brondeau and Sandifer had actual knowledge of, or access to, non-public information concerning the distributor inventory problems and the resulting constraints on replenishment orders. According to the complaint, defendants continued to describe the issue as temporary and addressed it only incrementally, while failing to disclose the need for a major pricing reset and the extent to which these conditions were impairing the company's financial outlook.
On October 15, 2026, FMC published preliminary third quarter 2026 results that fell materially below expectations. The complaint alleges that the release began to reveal the distributor-inventory problems. The company revised its quarterly revenue estimate to between $65 million and $125 million, with expected adjusted EBITDA of negative $565 million to negative $510 million. FMC disclosed that the critical commercial issue facing the company was slower-than-expected demand from channel customers, with distributors seeking to operate at the lowest inventory levels FMC had experienced. The company acknowledged that certain higher-priced products had increased the overall value of FMC inventory held by some customers, and that rapid market price declines, driven in part by increased generic competition, had widened the gap between the value of affected inventory and current market prices.
In the same release, Brondeau blamed weaker-than-expected third quarter demand on challenging market conditions and elevated levels of higher-priced FMC products held in inventory by certain channel customers. He acknowledged that the company had addressed the issue incrementally over several quarters, but that more comprehensive actions were necessary. The complaint alleges that these disclosures directly contradicted defendants’ earlier statements downplaying the distributor-inventory problems and describing weaker orders as temporary.
On October 29, 2026, FMC reported that the commercial actions announced on October 15 reduced third quarter revenue by $639 million. The company slashed its full-year 2026 outlook, projecting revenue excluding India of $2.75 billion to $2.85 billion, adjusted EBITDA of negative $124 million to negative $104 million, and adjusted EPS of negative $3.66 to negative $3.50. On the corresponding earnings call, Brondeau acknowledged that the channel inventory problem was constraining FMC's business and that management was forced to undertake more comprehensive corrective actions.
FMC shares fell after the October 15 announcement. The price of FMC common stock fell from a closing price of $8.09 per share on October 14, 2026 to $5.62 per share on October 15, 2026, a decline of approximately 31%. A number of analysts who had been following FMC lowered their price targets in response to the disclosures. Mizuho Securities cut its price target to $10.00 from $12.00, noting that the key question was whether the reset was sufficient to turn the ship. UBS cut its price target from $10.00 to $6.50, citing a high degree of uncertainty around whether a pricing floor had been reached and whether FMC could deliver the manufacturing cost reductions it needed. According to the complaint, the frequent, in-depth analyst discussion of FMC's shortfall confirms that defendants' statements during the class period were material.
● Lead Plaintiff Deadline: January 19, 2027
● After the lead plaintiff deadline, the Court will consider any lead plaintiff motions.
● Defendants may file a motion to dismiss.
● If the case proceeds, the Court may later consider class certification.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. Prior results do not guarantee similar outcomes.
The lawsuit alleges that FMC Corporation (NYSE: FMC) made materially false and misleading statements about its 2026 financial outlook between February 4, 2026 and October 14, 2026. According to the complaint, FMC projected revenue of $3.60 billion to $3.80 billion and adjusted EBITDA of $670 million to $730 million while concealing a worsening distributor-inventory problem. The complaint alleges that higher-priced inventory was difficult for distributors to sell, which impaired replenishment orders across FMC’s portfolio. The complaint further alleges that these undisclosed conditions made the company's financial outlook unlikely to be met, and that investors purchased FMC stock at artificially inflated prices.
The defendants are FMC Corporation and two of its senior executives. Pierre R. Brondeau served as Chairman of the Board and Chief Executive Officer at all relevant times. Andrew D. Sandifer served as Executive Vice President and Chief Financial Officer. According to the complaint, both individual defendants had the power and authority to control the contents of FMC's SEC reports, press releases, and presentations to analysts and investors. The lawsuit alleges they knew of, or had access to, non-public information concerning the distributor inventory problems and the constraints those problems placed on the company's sales and financial projections.
The class period runs from February 4, 2026 through October 14, 2026, inclusive. Investors who purchased or otherwise acquired FMC common stock during this period may be eligible to seek recovery under the federal securities laws. According to the complaint, FMC stock traded at artificially inflated prices throughout this period because of the alleged false and misleading statements about the company's financial outlook.
The price of FMC common stock fell after the company announced preliminary third quarter 2026 results that fell materially below expectations on October 15, 2026. FMC disclosed that distributors were seeking to operate at the lowest inventory levels the company had experienced and that elevated-priced products were increasingly difficult to move to growers. The stock fell from a closing price of $8.09 per share on October 14, 2026 to $5.62 per share on October 15, 2026, a decline of approximately 31%. Several analysts lowered their price targets in response.
According to the complaint, FMC concealed the extent of its distributor-inventory problem. The complaint alleges that elevated-priced inventory held by distributors was difficult to sell, which impaired replenishment orders across FMC's portfolio and threatened the company's ability to generate new sales, revenue, EBITDA, and cash flow. The lawsuit alleges defendants characterized weaker distributor orders as temporary shifts related to timing and inventory management, while failing to disclose the need for a major pricing reset. The complaint claims these conditions made FMC's full-year 2026 financial outlook unlikely to be met at the time defendants reaffirmed it.
The lead plaintiff deadline is January 19, 2027.
Several analysts lowered their price targets after FMC's disclosures. According to the complaint, Mizuho Securities cut its price target to $10.00 from $12.00, questioning whether the reset was sufficient to turn the ship. UBS cut its price target from $10.00 to $6.50, citing uncertainty around whether a pricing floor had been reached and whether FMC could achieve the manufacturing cost reductions it needed. J.P. Morgan maintained its underweight rating and described the third quarter results as tough. The complaint states that the in-depth analyst discussion of FMC's shortfall confirms the materiality of defendants' statements.
Investors who purchased or acquired FMC Corporation (NYSE: FMC) common stock during the class period from February 4, 2026 through October 14, 2026 may be eligible to seek recovery under the federal securities laws. Investors who wish to seek appointment as lead plaintiff must apply by the deadline. The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case who is adequate and typical of the class. After the lead plaintiff deadline, the Court will consider any lead plaintiff motions. Shareholders may consult a qualified attorney for guidance on their options.
The lawsuit alleges FMC Corporation (NYSE: FMC) made materially false and misleading statements about its 2026 financial outlook while concealing a distributor-inventory problem that impaired orders and threatened sales, revenue, EBITDA, and cash flow.
The class period runs from February 4, 2026 through October 14, 2026, inclusive. Investors who purchased or otherwise acquired FMC common stock during this period may be eligible to seek recovery under the federal securities laws.
FMC stock fell from $8.09 per share on October 14, 2026 to $5.62 per share on October 15, 2026, a decline of approximately 31%, after the company announced weak preliminary third quarter results.
The defendants are FMC Corporation, Chief Executive Officer Pierre R. Brondeau, and Chief Financial Officer Andrew D. Sandifer.
The lead plaintiff deadline is January 19, 2027.
Deadline
Jan 19, 2027